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Abstract
Background: Pelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular
imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this
moment, there are no specific treatment recommendations for patients with limited nodal recurrences and
different locoregional treatment approaches are currently being used, mostly by means of metastasis-directed
therapies (MDT): salvage lymph node dissection (sLND) or stereotactic body radiotherapy (SBRT). Since the majority
of patients treated with MDT relapse within 2 years in adjacent lymph node regions, with an estimated median
time to progression of 12–18 months, combining MDT with whole pelvic radiotherapy (WPRT) may improve
oncological outcomes in these patients. The aim of this prospective multicentre randomized controlled phase II trial
is to assess the impact of the addition of WPRT to MDT and short-term androgen deprivation therapy (ADT) on
metastasis-free survival (MFS) in the setting of oligorecurrent pelvic nodal recurrence.
Methods & design: Patients diagnosed with PET-detected pelvic nodal oligorecurrence (≤5 nodes) following radical
local treatment for PCa, will be randomized in a 1:1 ratio between arm A: MDT and 6months of ADT, or arm B: WPRT
added to MDT and 6months of ADT. Patients will be stratified by type of PET-tracer (choline, FACBC or PSMA) and by
type of MDT (sLND or SBRT). The primary endpoint is MFS and the secondary endpoints include clinical and
biochemical progression-free survival (PFS), prostate cancer specific survival, quality of life (QoL), toxicity and time to
castration-resistant prostate cancer (CRPC) and to palliative ADT. Estimated study completion: December 31, 2023.
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Discussion: This is the first prospective multicentre randomized phase II trial assessing the potential of combined
WPRT and MDT as compared to MDT alone on MFS for patients with nodal oligorecurrent PCa.
Trial registration: ClinicalTrials.gov Identifier: NCT03569241, registered June 14, 2018, ;
Identifier on Swiss National Clinical Trials Portal (SNCTP): SNCTP000002947, registered June 14, 2018.
Keywords: Prostate cancer, Oligometastases, Oligorecurrence, Stereotactic body radiotherapy, Whole pelvic radiotherapy,
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Background
A proportion of prostate cancer (PCa) patients develop a
local, regional (N1) or distant (M1) relapse following
curative local treatment. For both local and distant re-
lapse, different treatment recommendations are made in
the EAU-EANM-ESTRO-ESUR-SIOG guidelines on
Prostate Cancer [1]. The entity of regional nodal recur-
rence is not specifically mentioned in the guidelines al-
though it is an emerging clinical situation with the
introduction of new molecular imaging techniques like
choline and more recently PSMA PET-CT in the re-
staging of recurrent PCa [2]. More specifically, a sub-
group of these patients is being diagnosed with a
recurrence confined to the regional lymph nodes and
limited in number (oligorecurrence) using metabolic im-
aging [3, 4]. As there are no specific treatment recom-
mendations for limited metastatic disease, different
treatment approaches are currently used, mostly focus-
ing on local ablative treatment using radiotherapy or
surgery [5–8]. These treatments are coined metastasis-
directed therapy (MDT) [5]. MDT, whether or not in
combination with temporary androgen deprivation ther-
apy (ADT), has the potential to reduce the subsequent
risk of progression or even to cure limited regional nodal
recurrence [5], and hereby postponing or even pre-
empting the need for lifelong palliative ADT and its as-
sociated toxicity [9].
A recent systematic review showed that most pub-
lished series on MDT are small with heterogeneous pa-
tient populations, making it difficult to make treatment
recommendations [5, 7, 8]. To address these shortcom-
ings, an international patient database on oligometastatic
PCa recurrence (≤3 lesions) was established allowing to
study a homogeneous patient population treated with
stereotactic body radiotherapy (SBRT) [10]. A first ana-
lysis of this series showed that the majority of patients
treated with SBRT for nodal recurrence, relapse within 2
years in nearby lymph node regions, with an estimated
median time to progression of 12–18months [11–13].
Similar results in terms of time to progression were ob-
served in a large multi-institutional study exploring the
role of salvage lymph node dissection (sLND) after nodal
recurrence [14]. These comparable results could prob-
ably be explained by a lack of sufficient sensitivity of the
current imaging techniques to perform a lesion-based
approach, either by SBRT or sLND. An elective nodal ir-
radiation approach using whole pelvic radiotherapy
(WPRT) in addition to MDT could delay or even pre-
vent such relapse [12, 15–17]. Improved progression-
free survival (PFS) rates have been observed with WPRT
in radiotherapy series [15–17], as well as after sLND as
demonstrated in the retrospective study by Rischke et al.
[12].
The current trial wants to explore the potential benefit
in terms of metastasis-free survival (MFS) of an elective
nodal approach by adding WPRT to either sLND or as
alternative to focal SBRT. The proposed trial randomizes
patients with oligorecurrent nodal PCa following pri-
mary PCa treatment to either MDT (sLND or SBRT) or
WPRT plus MDT (focal radiotherapy boost or sLND).
As two recent trials have suggested a progression-free
and even overall survival benefit by adding temporary
ADT to local therapy in case of biochemical recurrence
[18, 19], a positive effect could also be expected for re-
gional recurrence. Although the optimal duration of
ADT is unknown, a minimal duration of 6 months of
ADT seems advisable in this setting and is mandatory
for both arms.
This trial will improve our insights in the pattern of
recurrence following these treatment modalities with the
expectation that WPRT will reduce the number of nodal
relapses, improving MFS and postponing the need for
palliative systemic treatment while maintaining quality
of life (QoL).
Methods & design
This study is approved by the Ethics committee of the
Ghent University Hospital (EC/2018/0130) and is regis-
tered on both ClinicalTrials.gov (NCT03569241) and
Swiss National Clinical Trials Portal (SNCTP000002947).
This is a prospective multicentre randomized phase II trial
designed for patients with PET-detected pelvic nodal oli-
gorecurrence (≤5 nodes) following radical local prostate
treatment (radical prostatectomy [RP], primary radiother-
apy [RT] or both). In the standard arm A, patients will re-
ceive MDT by means of SBRT or sLND, combined with
short-term ADT (6months). In the experimental arm B,
WPRT will be added to MDT (focal radiotherapy boost or
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sLND) and short-term ADT (6months). It will be empha-
sized that the participation is voluntary and that the pa-
tient is allowed to refuse further participation in the
protocol whenever he wants, which will not prejudice the
patient’s subsequent care. Estimated study completion:
December 31, 2023.
Objectives
Primary endpoint
MFS: time between randomization and the appearance
of a metastatic recurrence (any M1) as suggested by cho-
line, FACBC or PSMA PET-CT/PET-MRI or death due
to any cause. In case of biochemical progression, re-
staging will be performed, preferably with the same
PET-tracer. In case of negative PET findings at biochem-
ical relapse, repeated PET imaging should be performed
on a 6-monthly basis or earlier if clinically indicated.
Secondary endpoints
 Clinical PFS: time between randomization and the
appearance of a new recurrence (any N1 or M1) as
suggested by PET-CT or PET-MRI, symptoms re-
lated to progressive PCa or death due to any cause.
 Local recurrence: evidence of a recurrence on
imaging inside the surgical or radiotherapy field.
Confirmation per biopsy is recommended. For
radiotherapy schedules, local response and local
progression is defined as per RECIST 1.1 criteria.
 Regional nodal recurrence: radiographic evidence
(PET-CT or -MRI) of lymphadenopathy in the
pelvis, outside the surgical or radiotherapy field.
Histologic confirmation is recommended, especially
in the absence of biochemical recurrence.
 Distant recurrence: appearance of distant metastases
(M1a, M1b, M1c) outside the pelvis evidenced by
PET-CT or -MRI.
 Biochemical PFS: time between randomization and
the day of the first recorded biochemical progression
(as defined below), clinical progression or death due
to clinical progression.
 RP at diagnosis: biochemical recurrence = PSA >
0.20 ng/mL, confirmed 2 weeks later.
 Prostate radiotherapy at diagnosis: biochemical
recurrence = PSA nadir + 2 ng/mL (Phoenix
definition).
 Patients whose PSA does not drop below 0.20 ng/
mL (if previous RP) or below the level before
treatment (if previous prostate radiotherapy) at time
of first response assessment at 3 months follow-up,
are considered as non-responders to treatment and
are considered to have a biochemical recurrence in
case a second measurement at least 2 weeks later
confirms a stable or rising PSA above this level.
 Time to start of hormonal treatment: time from trial
randomization to start of hormonal treatment.
 Time to castration-resistant disease: time from trial
randomization until castration resistant status as de-
fined in the EAU-guidelines [1].
 PCa-specific survival: time from trial randomization
until death due to PCa.
 Overall survival (OS): time from trial randomization
until death from any cause.
 Acute and late toxicity due to radiotherapy will be
assessed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 [20], with special attention for
rectal, gastro-intestinal and urinary adverse events.
Surgery related morbidity, e.g. intra-operative com-
plications (blood loss, injury to other pelvic organs
…), and post-operative surgical complications will be
scored using the Clavien-Dindo Classification of
Surgical Complications [21].
 Acute toxicity: occurring during and up to 3 months
after treatment completion.
 Late toxicity: occurring later than 3 months after
treatment completion.
 Quality of life (QoL) scoring using the EORTC
QLQ-C30 supplemented with QLQ-PR25. Raw
scores will be transformed to a linear scale ranging
from 0 to 100 according to the EORTC manual. The
multi-item scales of the QLQ PR-25 will be analysed
at both the individual item and the scale level. The
results will be presented in accordance with recent
guidelines for reporting health related QoL random-
ized controlled trials [22].
 Pattern of progression.
 Sensitivity/specificity of PET-imaging for the detec-
tion of nodal recurrences: limited to patients under-
going surgery.
 Biomarker discovery: to develop a miRNA panel
predictive for treatment response using whole
genome miRNA expression profiling [23].
Inclusion criteria
 Histologically proven initial diagnosis of
adenocarcinoma of the prostate.
 Biochemical relapse of PCa following radical local
prostate treatment (RP, primary RT or RP +/−
prostate bed [PB] adjuvant/salvage RT) according to
the EAU guidelines 2019 [1].
 Following RP, patients with a biochemical relapse
are eligible in case a nodal relapse is detected in the
pelvis even in the absence of prior postoperative PB
radiotherapy (adjuvant or salvage).
 In case of a suspected local recurrence following
primary RT, a biopsy should confirm local
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recurrence. Patients with a confirmed local
recurrence are eligible in case they also undergo a
local salvage therapy.
 Nodal relapse in the pelvis on choline, PSMA or
FACBC PET-CT or PET-MRI with a maximum of 5
positive nodal lymph nodes. The upper limit of the
pelvis is defined as the aortic bifurcation.
 WHO performance state 0–1
 Age ≥ 18 years
 Absence of any psychological, familial, sociological
or geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule; those conditions should be discussed with
the patient before registration in the trial.
 Before patient registration/randomization, written
informed consent must be given according to ICH/
GCP and national/local regulations.
Exclusion criteria
 Bone or visceral metastases
 Para-aortic lymph node metastases (above the aortic
bifurcation)
 Local relapse in the prostate gland or bed not
suitable for curative treatment
 Previous irradiation of the pelvic and/or para-aortic
nodes
 Serum testosterone level < 50 ng/dL or 1.7 nmol/L at
time of randomization
 Symptomatic metastases
 Lymph node metastases in previously irradiated
areas resulting in dose constraint violation
 Contraindications to pelvic radiotherapy (e.g.
chronic pelvic inflammatory bowel disease)
 Contraindications to ADT
 PSA rise while on active treatment with ADT
(LHRH-agonist, LHRH-antagonist, anti-androgen,
estrogen)
 Previous treatment with a cytotoxic agent for PCa
 Treatment during the past month with products
known to influence PSA levels (e.g. fluconazole,
finasteride, corticosteroids …)
 Other active malignancy, except non-melanoma skin
cancer or other malignancies with a documented
disease-free survival for a minimum of 3 years before
randomization.
 Patients can only be randomized in this trial once.
Pre-randomization and evaluation
Patients must be restaged within 8 weeks prior to
randomization with either a whole-body choline, PSMA
or FACBC PET-CT/−MRI to exclude M1 disease (para-
aortic node(s), bone or visceral metastases). Additional
imaging modalities to confirm or to rule out M1 disease
are optional. For patients without prior RP it is recom-
mended to perform a multiparametric MRI of the pros-
tate to rule out local recurrence. Local relapses must be
biopsy proven. The following pre-treatment work-up,
which is also depicted in Table 1, must be performed:
Within 8 weeks prior to randomization
 Signed ICF
 Whole-body choline, PSMA or FACBC PET-CT/
PET-MRI
 Medical history (including previous therapies and
PSA values)
 In- and exclusion criteria
Within 2 weeks prior to randomization
 Patient characteristics
 Baseline symptoms (including gastrointestinal and
genitourinary morbidity) and medication
 QoL questionnaires (QLQ-C30, QLQ-PR25)
 Physical examination including scoring of
Performance Status, weight and height
 Baseline pre-treatment PSA and testosterone
determination
 Biomarker collection
Randomization
Treatment will be allocated at random in a 1:1 ratio
using Clinsight® online randomization system. Patients
will be stratified according to the type of PET-tracer
used (choline, PSMA or FACBC) and the type of MDT
(SBRT or sLND) (Fig. 1). As this is an open label trial,
randomization will not be blinded.
Patients will be randomized to receive one of the fol-
lowing treatments (Fig. 1):
Arm A:
 sLND + 6months of ADT or
 SBRT (30 Gy in 3 fractions) + 6 months of ADT
Arm B:
 sLND + WPRT (45 Gy in 25 fractions) + 6 months
of ADT or
 WPRT with simultaneous integrated boost (45 Gy in
25 fractions with SIB up to 65 Gy) + 6 months of
ADT
Evaluation during treatment
Following sLND:
 Physical examination including Performance score at
discharge
 PSA measurement at the first postoperative visit (4
weeks)
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 Toxicity assessment using Clavien-Dindo scale at
discharge
 Concomitant medication
 Operating characteristics: surgical technique,
operating time, blood loss, number of nodes
removed per lymph node region, number of positive
Table 1 Summary of study visits and procedures
TIMEPOINT STUDY PERIOD
Screening Allocation Treatment period Follow-up period
Within 8
weeks prior to
randomization
Within 2
weeks prior to
randomization
Baseline Start During End 1 month
after
treatment
± 7 days
3 months
after
treatment
± 14 days
6 months
after
treatment
± 14 days
6-monthly,
yearly, until
progression
(g)
± 14 days
Window
ENROLMENT:
Eligibility screen x
Signed ICF x
Randomization x
INTERVENTIONS (a,b):
If sLND x x x
If WPRT x x x
If SBRT x x x
ADT x x x x x x
ASSESSMENTS:
Medical history x
Patients characteristics x
Physical exam (c) x x x x x x
Lab
PSA x x (h) x x x x
Testosterone x x x x x
Biomarker x x (i)
Imaging
PET-CT (d) x (x) (x) (x)
MRI (e) x
Adverse Events
Baseline toxicity x
Acute toxicity (f) (x) (x) x x x
Late toxicity x x
Medication
Prior medication x
Con med’s x x x x x
Quality of life
QLQ-C30 x x x x
QLQ-PR25 x x x x
Survival status x x x x
(a) All arms should receive an LHRH-agonist or antagonist for a duration of 6 months using 1 monthly formulations. In case of SBRT/WPRT, ADT should start no later than the
first fraction (whichever RT treatment comes first) and no earlier than 2 weeks before the start of radiotherapy. In case of sLND, ADT should be started no earlier than 1 day
postoperatively and no later than 10 days postoperatively
(b) Treatment should start preferably within 4 weeks after randomization, but no later than 8 weeks after randomization. Treatment period is defined as the time between first
treatment day and last treatment of surgery and/or radiotherapy
(c) Physical examination including scoring of Performance Status. Weight and height will only be measured at screening
(d) Whole body choline, PSMA or FACBC PET-CT/−MRI. During follow-up repeat PET-CT only at time of biochemical relapse and then 6-monthly afterwards until clinical
progression is determined or earlier in case of symptomatic progression
(e) Optional: for patients without a prior radical prostatectomy it is recommended to perform a multiparametric MRI of the prostate to rule out local recurrence
(f) During the treatment period a toxicity assessment should be done at least once a week in case of WPRT. For SBRT toxicity assessment should be done only at end of
treatment, for sLND at discharge (Clavien-Dindo scale)
(g) 6-monthly follow-up for a minimum of 24months, with yearly follow-up thereafter up to 60months or until progression. In case of clinical progression, the patient will be
treated according to the EAU guidelines
(h) In case of SBRT/WPRT, PSA has to be determined on the day of the last fraction. In case of sLND in arm A, PSA will be determined at 4 weeks after surgery (follow-up
month 1). In case of sLND + WPRT in arm B, PSA will be determined at 4 weeks post-WPRT (follow-up month 1)
(i) At time of primary endpoint is reached, a new biomarker sampling is preferred, but optional
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nodes per lymph node region, indicate lymph node
regions sampled.
 Nodes should be sent in separate containers for
histopathological analysis.
WPRT or SBRT:
 Physical examination at the end of treatment
 Acute toxicity assessment (once a week for WPRT;
for SBRT at the end of treatment): the highest grade
of adverse events during radiotherapy will be
reported at the end of treatment.
 Concomitant medication
 Treatment planning
 Record planning results
Follow-up
Follow-up is planned at month 1, 3 and 6 following
treatment completion, 6-monthly thereafter until month
24 and then yearly up to month 60. Patients who with-
draw from trial treatment in the absence of progression
should continue to have follow-up visits as defined
above. The following investigations should be performed
at every follow-up visit (Table 1):
 Clinical examination with late toxicity scoring
 PSA and testosterone measurement
 QoL-scoring
 PET-imaging only at time of biochemical
progression or symptomatic progression and then 6-
monthly thereafter until clinical progression is deter-
mined. In case of biochemical progression, the PSA
should at least be 0.50 ng/mL before a new PET-CT
scan should be considered. The location of progres-
sion should be recorded.
 At time of primary endpoint is reached, a new
biomarker sampling is preferred, but optional.
 Concomitant medication
 Survival status
In case of clinical disease progression the patient will
be treated according to each centre policy, but adher-
ence to the EAU guidelines [24] is recommended. In
case of local or regional oligometastatic recurrence dur-
ing follow-up, a new MDT is allowed (this treatment
falls outside the scope of this protocol).
Interventions
General information
All patients will be presented at the multidisciplinary ur-
ology tumour board prior to treatment. The choice of
MDT (SBRT or sLND) will depend on the localization
and size of the metastases, the nearby organs at risk
(OAR) and previous treatment in the vicinity of the
metastases.
In case of a biopsy-confirmed local recurrence a local
therapy should be provided for a patient to be eligible.
Local radiotherapy to the PB is highly recommended in
case of pT3a/b-4 and/or R1 disease, or in case of a PSA
level ≥ 2 ng/mL, even if imaging rules out a local relapse.
In case of randomization to arm A, PB-RT can either
follow sLND or SBRT, or can be combined with SBRT.
In case of randomization to arm B, PB-RT radiotherapy
should be combined with WPRT.
Fig. 1 Trial design. PCa = prostate cancer, MDT =Metastasis-directed therapy, sLND = salvage lymph node dissection, SBRT = stereotactic body
radiotherapy, ADT = androgen deprivation therapy, WPRT =whole pelvic radiotherapy, RT = radiotherapy
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Radiotherapy
1. Positioning and CT simulation:
CT simulation has to be performed in supine
position by using an individualized immobilization
device in the treatment position on a flat table. The
use of i.v. contrast is highly recommended, as well
as the use of leg and knee support. It is
recommended that patients are scanned and treated
with comfortably full bladder and for PB-RT with
an empty rectum. If an MRI is used for co-
registration (recommended for PB-RT), the same
position for both the planning CT and MRI is rec-
ommended. The position of the patient will be
reproduced using skin marks and orthogonal laser
beams during treatment preparation and execution.
 For WPRT or PB-RT: CT slice thickness should be
5 mm or less. The planning CT should include at
least the pelvis from the lower part of the second
lumbar vertebra (L2) to the lower part of the ischial
tuberosities. The entire target volume and all OAR
must be included in the CT scan. The clinical target
volume (CTV), planning target volume (PTV) and
OAR must be delineated on all CT slices in which
these structures are visible.
 For SBRT: CT slice thickness should be 3 mm or
less. The planning CT scan should extend at least
10 cm superior and inferior beyond the treatment
field borders. Multiple isocentres and a sum plan
might be necessary for multiple suspicious nodes. A
CBCT prior to every treatment-isocentre is needed.
2. Organs at risk:
Delineation of OAR should be according to the
RTOG guidelines. Dose constraints to OAR for
WPRT are in agreement with the QUANTEC
guidelines [25–27] and the doses to OAR for SBRT
are stipulated in the AAPM report 101–3 fractions
schedule [28].
3. Definition of target volumes:
 The gross target volume (GTV) will be defined as all
known gross disease before any treatment, defined
by CT/MRI/PET-CT images and/or clinical
information. A GTV_PB may be defined with the
help of MRI and PET imaging.
 The CTV will encompass regions at risk of
microscopic extension. For CTV_PB, consensus
guidelines such as EORTC, RTOG or FROGG are
being followed [29–31]. The CTV_LNN consists of
the pelvic lymph node regions as described in the
RTOG guidelines [31], with the exception that
delineation of the common iliac lymph nodes should
start at the L4/L5 interspace [32] and should
encompass the GTVs. No CTV is mandatory for
SBRT.
 The PTV (PTV_PB, PTV_SBRT and PTV_LNN) will
provide margin around the CTV to compensate for
variability in daily treatment set-up and internal
CTV motion due to breathing or motion during
treatment. PTV_PB is created by a 5 to 10 mm mar-
gin for centres with or without image-guided radio-
therapy, respectively. The PTV_LNN must include
the entire CTV_LNN plus a minimum 3D-margin of
5 mm. For the nodal GTVs located within
CTV_LNN, a margin of 5 mm is used. The
PTV_SBRT should encompass the GTV with a min-
imal margin of 3 mm in all directions.
4. Dose prescription:
Intensity modulated radiotherapy (IMRT) or use of
rotational techniques is mandatory in case of
WPRT and SBRT. In case of SBRT, treatment with
Cyberknife® is allowed. 3D conformal technique is
not allowed in this trial.
 WPRT or PB-RT:
All fields and the entire PTV_LNN must be treated
daily for 5 days per week in a once-daily schedule of
1.8 Gy per fraction, for a total dose of 45 Gy in 25
fractions. The GTV should receive an integrated
boost to a median dose of 65 Gy in 25 fractions, 2.6
Gy per fraction. If a suspicious node is still present
following sLND, it is allowed to boost the GTV to
the same dose during WPRT. In case of PB-RT, the
PTV_PB should receive at least 66 Gy in 33
fractions.
Normalization of the treatment plan will cover 95% of
the PTV_LNN or PTV_PB with the prescription dose.
Furthermore, 98% of the PTV_LNN or PTV_PB should
receive 95% of the prescription dose with 2% of the PTV
not exceeding 107% of the prescribed dose.
 SBRT (MDT):
A total dose of 30 Gy (80% of the maximal dose) will
be delivered in 3 fractions and fractions will be
separated > 48 h and < 96 h. Treatment will be
prescribed to the periphery of the target (80% of the
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dose (= 30 Gy), should cover 90% of the PTV). In
case of violation of dose constraints to the
surrounding OAR, the prescription will be adapted
accordingly.
Surgery – sLND (MDT)
A bilateral extended lymph node dissection of the true
pelvis will be performed either via an open or minimally
invasive approach, which is at the discretion and expert-
ise of the surgeon. A minimally invasive technique is
preferred, but not mandatory. In case of pelvic nodal up-
take, all nodal/fibrofatty tissue at the external and in-
ternal iliac regions and obturator fossa region will be
removed. For pelvic nodal metastases, in case of a previ-
ous extended lymphadenectomy, only the suspicious
lymph node(s) will be removed. The definition of the
true pelvis is defined according to the AJCC Cancer Sta-
ging Manual 7th edition and the regions are defined by
Mattei et al. [33]. An extended lymph node dissection of
regions I and II is recommended in this study.
In case of WPRT after sLND in arm B: WPRT should
start between the 4th and 12th week following sLND. In
case the morbidity of sLND does not allow a safe start of
RT in this period, radiotherapy will not be carried out.
Androgen deprivation therapy
All arms should receive an LHRH-agonist or -antagonist
for a duration of 6 months using 1-monthly formula-
tions. In case of LHRH-agonist, flare prevention with an
anti-androgen is recommended for at least 5 days prior
to the first injection of the agonist and should not be
continued for longer than 15 days of the first month
duration. ADT-related toxicity should be managed ac-
cording to Nguyen et al. [34].
 In case of sLND, ADT should be started between
day 1 and day 10 postoperatively.
 In case of SBRT/WPRT, ADT should start no later
than the first day of WPRT and no earlier than 1
week before the start of SBRT/WPRT.
Palliative ADT should not be started for biochemical
progression without documented clinical progression. In
case of symptomatic progression, palliative ADT is
mandatory. In case of clinical asymptomatic progression,
delayed ADT until progression to a symptomatic state is
allowed in well informed men (EAU 2019 guidelines). In
general, starting ADT in asymptomatic patients is rec-
ommended only if conventional imaging confirms clin-
ical progression. The start of ADT for PET-positive
lesions not suspicious on conventional imaging (CT/
MRI/bone scintigraphy) is not recommended. In case of
clinical oligometastatic progression, repetition of MDT
is allowed for all arms.
Statistical analysis
Sample size
This prospective randomized phase II design aims to de-
termine whether the treatment arm can be tested in a
subsequent phase III trial. Patients will be randomized
(1:1) to receive either arm A: MDT (sLND or SBRT)
plus ADT or arm B: WPRT plus MDT (focal radiother-
apy boost or sLND) plus ADT. Stratification is according
to the type of MDT and the type of PET-tracer. The
sample size is based on the stratified Log-rank test. A
scenario analysis has been performed to reflect the dif-
ferent and reasonable possible values of the parameters.
The two-sided significance level alpha was set at 0.20
and the power maintained at 80%. In this chosen sce-
nario, the median MFS following MDT has been esti-
mated as 24 months in arm A. Assuming uniform
accrual over 48 months with 24months additional
follow-up time, a total of 178 patients are needed to de-
tect a 12-month difference in median MFS from 24 to
36months, considering a 5% rate of loss to follow-up.
The total study length will be 72 months.
Data analysis
Patients will be analysed in the group to which they are
assigned. The probability of MFS, PFS and OS will be es-
timated using the Kaplan-Meier Survival Analysis
method. Stratified log-rank tests will be performed to
compare PFS and OS between the two treatment arms.
Cox proportional hazards models will be fit to assess the
effects of treatment and baseline clinical and pathologic
features (such as PSA, PSA doubling time, Gleason score
etc.) on MFS, PFS or OS. All p-values are set at 0.20 for
primary analysis and at 0.05 for other analyses. Statistical
analysis will be performed with SPSS version 25 (IBM,
Armonk, NY, USA) and R version 3.5.3.
Data management and monitoring
Study data will be stored in a digital archive developed
in cooperation with Methodology, Biostatistics and Data
Management unit, Centre Georges François Leclerc,
Dijon, France, that will make use of a clinical trial com-
patible eCRF based on the web-based data capture sys-
tem Clinsight®. Current international requirements for
data protection will be followed. Health related personal
data captured during this project are strictly confidential
and accessible only by investigators and authorized
personnel; disclosure to third parties is prohibited. Cod-
ing will safeguard participants’ confidentiality. No on-
site quality control or audits will be foreseen.
In order to avoid introducing bias, no interim analysis
will be performed. There is no anticipated harm and
compensation for trial participation. Serious adverse
events will be reported to the UZ Ghent Ethical Com-
mittee and the local Ethics Committee and must be
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followed up for outcome. After completing the trial, par-
ticipants will be followed by the radiation oncologist and
urologist.
Translation research
In patients willing to provide a blood sample, we aim to
collect both serum and plasma samples at baseline in a
standardized manner. These samples will be used to
identify potential prognostic or predictive biomarkers
that might help us identify the ideal patient for different
approaches. In patients undergoing sLND, FFPE tissue
can be compared with the blood-based markers. De-
pending on the evolution of the different techniques
over the trial period, specific biomarkers will be evalu-
ated among others, but not limited to miRNA, cfDNA,
cfRNA.
Radiotherapy quality assurance
Quality assurance (QA) for this multicentre trial follows
the nomenclature of The Global Clinical Trials Quality
Assurance of Radiation Therapy Harmonization Group
(GHG) [35] and the Radiation Therapy Quality Assur-
ance (RTQA) procedures of the European Organisation
for Research and Treatment of Cancer (EORTC) [36].
The QA consists of a site and study specific question-
naire (SSQ) encompassing a facility questionnaire and a
proof of beam output audit. A two-phase benchmark
case is run. In phase I participating centres submit the
delineation of a SBRT and WPRT-case for comparison
to reference contours. In phase II the centres perform a
dose-planning of a SBRT and WPRT-case using refer-
ence contours and verify the delivery with a complex
dosimetry check according to the institution’s clinical
practice. No individual case review is foreseen in this
trial.
Participating sites
This multicentre study is currently conducted at follow-
ing sites:
– Belgium: Ghent University Hospital; Iridium Cancer
Network, GZ Antwerp; AZ Groeninge, Kortrijk;
Leuven University Hospital; Jules Bordet Institut,
Bruxelles; AZ Maria-Middelares, Ghent.
– Switzerland: Geneva University Hospital; University
Hospital Basel; Bern University Hospital; University
Hospital Zürich; Kantonsspital St. Gallen.
– Spain: Cruces University Hospital, Barakaldo;
University Hospital La Princesa, Madrid; Hospital
Universitari i Politècnic la Fe, Valencia.
– Italy: Humanitas Research Hospital Milan.
– Norway: Oslo University Hospital.
– Australia: Epworth Healthcare, Melbourne.
All participating centers have experience in research
within the urological oncological field. Data collection in
these hospitals enables the study to include enough pa-
tients and gives the study sufficient power.
Discussion
The entity regional nodal oligorecurrent PCa is not
mentioned in the treatment guidelines but is an emer-
ging clinical situation since the introduction of new mo-
lecular imaging techniques, such as choline and more
recently PSMA PET-CT, in the restaging of recurrent
PCa [2–4]. As there are no specific treatment recom-
mendations for patients with limited metastatic disease,
different treatment approaches are currently used,
mostly by means of MDT (sLND or SBRT) to delay dis-
ease progression and to postpone androgen ablation
treatments [5, 6]. Although MDT approaches represent
potential effective treatment options for oligorecurrent
patients according to the APCCC expert consensus
meeting [37, 38], available treatment results are mostly
based on retrospective series, including an overall low
number of treated patients with a limited follow-up and
several heterogeneities in the treatment modalities pro-
posed. The best treatment approach for patients with
oligorecurrent nodal disease remains therefore debated.
The only prospective data available in literature have
been reported by a single centre non-randomized study
(POPSTAR) [39] and a randomized phase II trial
(STOMP) [40], both using SBRT. SBRT directed to the
single nodal relapse has the advantage to deliver highly
conformal irradiation with very high radiotherapy doses
in only few fractions (3 to 10) over a short overall treat-
ment time (OTT). Major potential benefits of this tech-
nique arise from excellent local tumour control, a
negligible acute toxicity, an excellent patient’s compli-
ance, the possibility for repeated SBRT treatments for
outfield relapses and a possible immune-mediated im-
pact on the tumour growth outside the RT field (absco-
pal effect). For sLND, only retrospective data are
available. The expected benefit of this technique is the
pathological validation of removed lymph nodes and the
removal of false PET-negative lymph nodes in a prede-
fined elective area of the pelvis. Fossati et al. observed in
a recently published series that in patients with ≥3 posi-
tive spots on choline or PSMA PET/CT at time of recur-
rence, the number pathologically involved nodes
detected by sLND was twice as high [14]. Salvage pelvic
LND however is an invasive procedure with potential
complications and long-term morbidity, even in experi-
enced centres.
Although sLND is not a pure lesion-directed approach,
the recurrence patterns of both SBRT and sLND are
comparable with > 60% of patients relapsing in adjacent
lymph node regions [11–13]. This might be explained by
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the fact that even the most extended sLND does not
cover all potential pelvic lymph node metastasis landing
sites. In a previous paper from our group, we indicated
that an extended sLND technique only covers around
50% of these sites [41]. Consequently, we hypothesize
that a larger RT field covering the elective nodal regions
in a treatment field may be a more effective alternative
to focal strategies. This is supported by a retrospective
study by Rischke et al. [12], indicating a reduced pelvic
lymph node recurrence rate following sLND plus WPRT
as compared to sLND alone. On the other hand, com-
pared to MDT strategies, longer OTT, higher toxicity
rates and limited re-treatment possibilities are expected
by delivering elective nodal irradiation. Nevertheless,
WPRT grade 3 toxicity rates appear to be low in recent
trials such as OLIGOPELVIS and SPPORT [42, 43].
In both arms, short term ADT will be mandatory. The
rationale for the use of temporary ADT is extrapolated
from the data in the salvage setting (GETUG16,
RTOG9601, SPPORT, OLIGOPELVIS), indicating that
temporary ADT reduces the rate of biochemical and
clinical recurrences [12, 18, 19, 42, 43]. There are no
clear guidelines on the ideal duration of ADT in this set-
ting, so we opted for 6 months as studied in GETUG16,
OLIGOPELVIS and SPPORT [19, 42, 43].
As no direct comparison of the two approaches have
been made to date, prospective studies using well-
defined endpoints and predefined treatment approaches
are therefore needed to validate the best treatment ap-
proach in the nodal oligorecurrent setting. The STORM
study will be the first prospective multicentre random-
ized controlled phase II trial to assess the possibility of
prolonging the MFS by adding WPRT to either sLND or
SBRT, both in combination with short-term ADT in
PCa patients with nodal oligorecurrent disease.
Supplementary information
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1186/s12885-020-06911-4.
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